The case for & against
Bull & Bear analysis
Envista Holdings Corporation (NYSE: NVST) is a leading provider in the dental supplies industry, offering a diverse portfolio that spans orthodontic devices, dental implants, and advanced imaging systems. The company has established itself as a significant player in the dental market by focusing on innovation and operational excellence, catering to both dental service organizations (DSOs) and individual practitioners. Envista's broad product offerings and commitment to research and development position it favorably within the ongoing transformation of dental care amidst macroeconomic challenges and competitive pressures.
Bull says
- ↑Q1 revenue $706M (+9.5% YoY) and adjusted EPS $0.36 (+50% YoY)
- ↑Adjusted EBITDA $99M (+25% YoY) and net income $38.7M (+115% YoY)
- ↑Guidance targets ~100% free cash flow conversion in 2026 with strong balance sheet enabling $300M repurchase
- ↑Innovation-led launches (Spark aligner, DTX Studio Clinic) driving product demand
- ↑High earnings yield and above-average book-to-price signal undervaluation
- ↑Easing inflation and stable dental market support continued revenue expansion
Bear says
- ↓Q1 free cash flow negative $15.8M highlights cash volatility
- ↓Tariffs cut margins by ~60bps; weak profitability factor evident
- ↓Core growth ex-calendar effect ~4%; weak growth factor underlines slowdown
- ↓Value-based pricing reforms in China create regulatory uncertainty
- ↓High sensitivity to oil prices risks rising operational costs
- ↓Elevated short interest reflects investor skepticism
Investment themes with NVST
Companies that recently went public
Devices and instruments for medical treatment
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- Q1 was a good start to 2026 for Invista, extending the momentum we built across 2024 and 2025.
- we posted 9.5% core growth in Q1, and for the fourth straight quarter now, all of our major businesses delivered positive growth.
- Ortho, consumables, and diagnostics were all up double digits, and implants was up mid-single digits, excluding China.
Bear points
- our Q1 free cash flow was negative 16 million, a reduction of about $11 million from the first quarter of last year, primarily driven by an increase in CapEx as we invest in new manufacturing facilities in China and Finland to support our growth objectives.
- C1 free cash flow was negative $16 million, a reduction of about $11 million from the first quarter of last year, primarily driven by an increase in CapEx as we invest in new manufacturing facilities in China and Finland to support our growth objectives.
- C1 free cash flow was negative $16 million, a reduction of about $11 million from the first quarter of last year, primarily driven by an increase in CapEx as we invest in new manufacturing facilities in China and Finland to support our growth objectives.